CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients by Schrevel, M. et al.
CXCR7 expression is associated with disease-free and
disease-specific survival in cervical cancer patients
M Schrevel1, R Karim2,3, NT ter Haar1, SH van der Burg3, JBMZ Trimbos4, GJ Fleuren1, A Gorter*,1
and ES Jordanova1
1Department of Pathology, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC Leiden, The Netherlands; 2Department of
Immunohaematology and Blood Transfusion/Center for Human and Clinical Genetics, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC
Leiden, The Netherlands; 3Department of Clinical Oncology, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC Leiden, The Netherlands;
4Department of Gynaecology, Leiden University Medical Center (LUMC), PO Box 9600, 2300 RC Leiden, The Netherlands
BACKGROUND: The CXC chemokine receptor (CXCR)7 is involved in tumour development and metastases formation. The aim of the
present study was to determine protein expression of CXCR7, its putative co-receptors epidermal growth factor receptor (EGFR)
and CXCR4, its predominant ligand CXCL12, their co-dependency and their association with survival in cervical cancer patients.
METHODS: CXC chemokine receptor 7, EGFR, CXCR4 and CXCL12 expression were determined immunohistochemically in
103 paraffin-embedded, cervical cancers. Subsequently, associations with patient characteristics were assessed and survival analyses
were performed.
RESULTS: CXC chemokine receptor 7 was expressed by 43% of tumour specimens, in a large majority of cases together with either
EGFR or CXCR4 (double positive), or both (triple positive). The CXCR7 expression was associated with tumour size (P¼ 0.013),
lymph node metastasis (P¼ 0.001) and EGFR expression (P¼ 0.009). CXC chemokine receptor 7 was independently associated
with disease-free survival (hazard ratio (HR)¼ 4.3, 95% confidence intervals (CI) 1.7–11.0, P¼ 0.002), and strongly associated with
disease-specific survival (HR¼ 3.9, 95% CI 1.5–10.2, P¼ 0.005).
CONCLUSION: CXC chemokine receptor 7 expression predicts poor disease-free and disease-specific survival in cervical cancer
patients, and might be a promising new therapeutic marker. In a large majority of cases, CXCR7 is co-expressed with CXCR4 and/or
EGFR, supporting the hypothesis that these receptors assist in CXCR7 signal transduction.
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Cervical cancer is the third most common type of cancer among
women worldwide, accounting for 9% of all new cancer cases
among females in 2008 (Jemal et al, 2011). Although screening for
premalignant stages of cervical cancer and vaccination with the
available human papillomavirus (HPV)-vaccines are good options
to prevent cervical carcinogenesis, treatment options are limited
when women present with advanced cancer stages. Partly, this is
because the mechanisms involved in tumour cell invasion and
metastasis formation, which strongly predict mortality rates, are
not fully understood. Furthermore, markers that accurately predict
response to therapy are limited. Additional predictive molecular
markers for lymph node metastases and disease-free survival may
help to elucidate these mechanisms.
A promising new marker is the CXC chemokine receptor
(CXCR) 7. CXC chemokine receptor 7 is transcribed from the
RDC1-gene on chromosome 2, where the genes encoding CXCR1,
CXCR2 and CXCR4 are also localised (Balabanian et al, 2005). CXC
chemokine receptor 7 is strongly expressed in many different
tumour types and on tumour-associated vasculature, whereas
expression in most normal tissues is weak or absent. The CXCR7 is
involved in cell survival, cell adhesion, tumour development and
metastases formation (Burns et al, 2006; Miao et al, 2007).
Expression of CXCR7 has not been determined in cervical cancer,
but has been associated with a higher tumour grade and more
aggressive tumour growth in other cancer types, such as prostate
cancer, non-small cell lung cancer, breast cancer, glioma and
hepatocellular carcinoma (Miao et al, 2007; Wang et al, 2008;
Iwakiri et al, 2009; Hattermann et al, 2010; Zheng et al, 2010).
However, most studies have been performed on tumour cell lines
and mouse models, and studies addressing the association between
CXCR7 expression and prognosis in patient-derived tumour
material are limited.
Two ligands bind to CXCR7, namely CXCL11 (interferon-
inducible T-cell a chemoattractant) and CXCL12 (stromal cell-
derived factor-1). In cell lines, activation of CXCR7 by CXCL12
induced trans-endothelial migration, whereas CXCR7 antagonists
and CXCL11 both inhibited cellular migration (Zabel et al, 2011).
Furthermore, CXCL12 expression was associated with overall
and disease-free survival in pancreas carcinoma, suggesting
that CXCL12 is the predominant ligand associated with
CXCR7-mediated metastasis formation (Liang et al, 2010).
Conflicting results have been published on the intracellular
signalling pathways of CXCR7, as ligand binding does not result in
typical CXC receptor Gi-mediated signalling (Thelen and Thelen,
2008). It is still unclear whether the receptor is able to activate
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other signal transduction pathways. It has been proposed that
CXCR7 heterodimerisation with other signalling receptors such as
the epidermal growth factor receptor (EGFR) or CXCR4 is required
to induce intracellular signalling (Hartmann et al, 2008; De´caillot
et al, 2011; Singh and Lokeshwar, 2011). Both EGFR and CXCR4
expression have been shown to be associated with lymph node
metastases and disease-free survival in cervical cancer
(Kersemaekers et al, 1999; Kodama et al, 2007; Schrevel et al, 2011).
The aim of the present study was to determine protein
expression of CXCR7, its putative co-receptors EGFR and CXCR4,
its main ligand CXCL12, their co-dependency and their association
with survival in cervical cancer patients. Therefore, we immuno-
histochemically determined CXCR7, EGFR, CXCR4 and CXCL12
expression, and assessed the association between protein expres-
sion and patient characteristics. Furthermore, we analysed whether
(co-)expression of CXCR7, EGFR and CXCR4 was associated with
disease-specific and disease-free survival.
MATERIALS AND METHODS
Subjects
Formalin-fixed, paraffin-embedded primary tumour tissue sam-
ples from 103 cervical cancer patients who underwent radical
hysterectomy with lymphadenectomy between January 1985 and
December 1999 were collected from the archives of the Department
of Pathology, Leiden University Medical Center (Leiden,
the Netherlands). Patients had not received radiotherapy or
chemotherapy before surgery. Postoperative radiotherapy was
indicated in patients with lymph node metastasis, parametrial
involvement or positive resection margins. Clinical and follow-up
data were taken from patient medical records. Disease-specific
survival and disease-free survival were assessed to determine the
time to cancer-related death and disease recurrence, respectively.
Disease-specific survival time was assessed from the date of
surgery to the date of cancer-related death or the date of the last
follow-up visit for censored observations. For disease-specific
survival, patients who died of a cause unrelated to cervical cancer
were considered as censored observations at the date of death. The
end point for disease-free survival was the date of local or regional
recurrence or the date of distant metastasis.
Tumours were HPV-typed by general primer PCR and sequen-
cing, as described by Koopman et al (1999). In addition to the
tumour samples, two specimens of normal cervical epithelium
were obtained from two patients with no history of cervical cancer.
This number of healthy tissue samples was sufficient, as the
staining of CXCR4, CXCR7 and CXCL12 was expected to be similar
for all normal cervical epithelium specimens. Tissue samples were
used according to the guidelines of the Ethical Committee of the
Leiden University Medical Center.
Immunohistochemistry
For immunohistochemical analysis, 4 mm tissue microarray (TMA)
slides consisting of triplicate punches of 103 cervical cancer
patients were deparaffinised and rehydrated. Endogenous perox-
idase was blocked with 0.3% hydrogen peroxide (H2O2) for 20min.
Antigen retrieval was performed in 0.01 M citrate buffer (pH¼ 6.0,
12min, microwave oven). Subsequently, slides were incubated
overnight at room temperature with anti-CXCR4 (1 : 600, IgG2a,
clone 2F1, Abnova, Heidelberg, Germany), anti-CXCR7 (1 : 50,
IgG1, clone 11G8, R&D Systems, Abingdon, UK) or anti-CXCL12
(1 : 50, IgG1, clone 79018, R&D Systems), diluted in phosphate-
buffered saline (PBS) containing 1% bovine serum albumin.
After washing with PBS, the TMA slides were incubated
for 30min with BrightVision-Poly/HRP (Immunologic, Duiven,
the Netherlands). Immunoreactions were visualised using 0.5%
3,30-diamino-benzidine-tetra-hydrochloride and 0.002% H2O2 in
Tris-HCl, after which the slides were counterstained with
haematoxylin. Immunoreactivity was scored as negative, weak,
moderate or strong staining intensity. Immunohistochemistry for
EGFR was performed as previously described, and EGFR was
scored for membrane staining intensity (Schrevel et al, 2011).
Statistical analyses
Statistical analyses were performed using the SPSS program
(Version 17.0 for Windows; SPSS Inc., Chicago, IL, USA).
Significance tests were two-sided and statistical significance was
assumed when Po0.05, corresponding to 95% confidence intervals
(CI). To assess whether CXCR7 expression was associated with
expression of its ligand CXCL12 or its proposed co-receptors EGFR
and CXCR4, the Spearman’s rank correlation test was performed,
as the intensity scores for CXCR7, EGFR, CXCR4 and CXCL12 were
ordinal. The w2 test was used to determine whether CXCR7, EGFR,
CXCR4 and CXCL12 expression was associated with clinicopatho-
logical characteristics, with protein expression data recoded into
binary variables. Univariate Cox-regression analysis was per-
formed to assess the association between clinicopathological
parameters, CXCR7, EGFR, CXCR4 and CXCL12 expression,
and disease-free survival. All analyses were repeated for disease-
specific survival. Multivariate Cox-regression analysis was per-
formed to determine whether CXCR7 expression was indepen-
dently associated with disease-free survival, when correcting for
HPV-type, histopathological diagnosis, tumour size, infiltration
depth, parametrial invasion, vasoinvasion, lymph node metastasis,
resection margins and postoperative radiotherapy. Corresponding
survival curves were estimated by the Kaplan-Meier method.
RESULTS
Patient characteristics in relation to CXCR7, EGFR,
CXCR4 and CXCL12 expression in cervical cancer
Immunohistochemical staining of CXCR7, CXCR4 and CXCL12
was observed to be both cytoplasmic and membranous in cervical
cancer specimens. Normal cervical epithelium stained weakly for
CXCR7, CXCR4 and CXCL12, with strong CXCL12 expression in
cells of the basal layer. Representative examples of positive and
negative CXCR7, EGFR, CXCR4 and CXCL12 cervical cancer
specimens are shown in Figure 1. The distribution of staining
intensities is shown in Table 1. CXC chemokine receptor 7, EGFR
and CXCL12 had a wider range in staining intensity, when
compared with CXCR4, as no strong positives were observed for
CXCR4. To assess whether CXCR7 expression was associated with
expression of its ligand CXCL12 or its proposed co-receptors EGFR
and CXCR4, the Spearman’s rank correlation coefficient (r; rho)
was determined. CXC chemokine receptor 7 expression was
significantly correlated with EGFR expression (r¼ 0.272,
P¼ 0.009), but not with CXCR4 expression (r¼ 0.117, P¼ 0.259)
or CXCL12 expression (r¼  0.028, P¼ 0.790). Compared with an
ideal correlation of 1, the observed Spearman’s r of 0.272 indicates
a moderate correlation.
Clinicopathological characteristics of the 103 cervical cancer
patients are summarised in Table 2. The median age at the time of
diagnosis was 48 years (range, 24–87). Positive CXCR7 expression
was associated with tumour size X40mm (odds ratio (OR)¼ 2.9,
95% confidence interval (CI) 1.2–6.8, P¼ 0.013) and lymph node
positivity at the time of surgery (OR¼ 5.7, 95% CI 2.0–16.1,
P¼ 0.001). CXC chemokine receptor 7 expression was observed
more frequently in squamous carcinoma than in adeno-/adenos-
quamous carcinoma (OR¼ 2.6, 95% CI 1.1–6.0, P¼ 0.025). Both
EGFR and CXCR4 expression were observed more frequently in
squamous/adenosquamous carcinoma than in adenocarcinoma
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(OR 26.6, 95% CI 3.3–217.4, Po0.001 and OR¼ 6.4, 95% CI
1.6–25.7, P¼ 0.008, respectively). No other associations were
observed between CXCR7, CXCR4, CXCL12 and clinicopatho-
logical characteristics. As previously described, EGFR expression
was associated with tumour size, parametrial invasion, vasoinva-
sion and lymph node metastasis (Schrevel et al, 2011).
Disease-specific and disease-free survival for CXCR7,
EGFR, CXCR4 and CXCL12
Median follow-up time was 137 months (range 5–266) for all
patients and 156 months (range 8–266) for patients alive at
the time of data collection. Of the 24 patients with disease
recurrence, a combination of local recurrences (n¼ 4), regional
recurrences (n¼ 3) and distant metastases (n¼ 20) was observed.
Of the 34 patients who died during the follow-up period, 22 deaths
could be attributed to cervical cancer. Five-year disease-free
and disease-specific survival rates for the whole group were
77% (s.e.¼ 4) and 79% (s.e.¼ 4), respectively. Univariate
Cox-regression analysis for all clinicopathological characteristics
and disease-free survival is shown in Table 2. Multivariate
regression analysis for all clinicopathological characteristics
showed that only tumour size (hazard ratio (HR)¼ 4.8, 95%
CI 1.8–12.3, P¼ 0.001) and lymph node metastasis (HR¼ 5.4, 95%
100 m 100 m
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Figure 1 Representative examples of positive (A) and negative (B) CXCR7 staining, positive (C) and negative (D) EGFR staining, positive (E) and
negative (F) CXCR4 staining, and positive (G) and negative (H) CXCL12 staining in the epithelial compartment of squamous cell carcinoma of the cervix.
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CI 2.3–12.7, Po0.001) were independently associated with
disease-free survival.
Univariate Cox-regression analysis for CXCR7 showed a strong
association between positive CXCR7 expression and disease
recurrence, with 63% vs 90% disease-free survival for CXCR7-
positive and CXCR7-negative cases, respectively, (HR¼ 4.3, 95%
CI 1.7–11.0, P¼ 0.002, Figure 2A, Table 3). CXC chemokine
receptor 7 expression was also associated with disease-specific
survival (HR¼ 3.9, 95% CI 1.5–10.2, P¼ 0.005). CXC chemo-
kine receptor 4 and CXCL12 expression were not associated with
disease-free (Table 3) nor disease-specific survival (data not
shown). There was a trend for a positive association between EGFR
expression and disease-free survival (HR¼ 2.3, 95% CI 0.9–6.4,
P¼ 0.095, Table 3).
Multivariate regression analysis showed that only CXCR7
expression (HR¼ 3.4, 95% CI 1.1–10.5, P¼ 0.030), tumour size
per mm increase in tumour size (HR¼ 1.1, 95% CI 1.0–1.1,
P¼ 0.001) and lymph node metastasis at the time of surgery
(HR¼ 4.5, 95% CI 1.2–16.8, P¼ 0.024) were independent pre-
dictors of disease-free survival, when correcting for HPV-type,
histopathological diagnosis, tumour size, infiltration depth, para-
metrial invasion, vasoinvasion, lymph node metastasis, resection
margins and postoperative radiotherapy. Multivariate regression
analysis for CXCR7, EGFR, CXCR4 and CXCL12 expression
showed that only CXCR7 was independently associated with
disease-recurrence (HR¼ 4.2, 95% CI 1.5–12.0, P¼ 0.007).
Disease-free survival for co-expression of CXCR7,
EGFR, CXCR4 and CXCL12
To assess whether co-expression of CXCR7 and its ligand CXCL12
was associated with disease-free or disease-specific survival,
groups were made for CXCR7-negative cases (n¼ 58) and
CXCR7-positive cases with (n¼ 33) or without CXCL12 expression
(n¼ 5). Survival analysis showed no difference between CXCR7-
positive/CXCL12-positive and CXCR7-positive/CXCL12-negative
cases (data not shown). To investigate whether co-expression of
CXCR7 and EGFR, CXCR4 or both was associated with disease-free
or disease-specific survival, groups were made for CXCR7-negative
cases (n¼ 58), CXCR7-positive cases with no EGFR or CXCR4
expression (single positive, n¼ 4), CXCR7-positive cases with
either EGFR or CXCR4 expression (double positive, n¼ 16) and
CXCR7-positive cases with both EGFR and CXCR4 expression
(triple positive, n¼ 21). As the survival curves for the 4 CXCR7
single-positive cases were comparable to the 58 CXCR7-negative
cases, these groups were combined for further analyses. Univariate
Cox-regression analysis showed equally increased risks of disease
recurrence for both double- and triple-positive cases when
compared with CXCR7-negative/single-positive cases (HR¼ 3.6,
95% CI 1.2–10.7, P¼ 0.022, and HR¼ 4.2, 95% CI 1.5–11.7,
P¼ 0.006, respectively, Figure 2B, Table 3). As expression of
CXCR7 was observed more frequently in squamous cell carcinoma
than in other histopathological types, regression analysis was also
performed for this subgroup. In squamous cell carcinomas, the
risk between disease-free survival and CXCR7-negative/single-
positive cases, double-positive cases and triple-positive cases
increased in an additive fashion (double: HR¼ 2.7, 95% CI
0.6–12.1, P¼ 0.193, triple: HR¼ 5.8, 95% CI 1.5–22.4, P¼ 0.011,
Figure 2C, Table 3). Survival analysis for disease-specific survival
showed similar results (data not shown).
Table 1 CXCR7, EGFR, CXCR4 and CXCL12 expression in cervical
cancer patients
Expression N (%)a
CXCR7
Negative 58 (57)
Weak 18 (18)
Moderate 20 (20)
Strong 5 (5)
EGFR
Negative 19 (20)
Weak 16 (17)
Moderate 31 (33)
Strong 28 (30)
CXCR4
Negative 36 (37)
Weak 51 (53)
Moderate 10 (10)
Strong 0 (0)
CXCL12
Negative 13 (14)
Weak 35 (38)
Moderate 28 (31)
Strong 16 (17)
Abbreviations: CXCR¼CXC chemokine receptor; EGFR¼ epidermal growth factor
receptor. aTotal number of assessed cases is 101 for CXCR7, 94 for EGFR, 97 for
CXCR4 and 92 for CXCL12. Protein expression was determined through analysis of
an immunohistochemically stained tissue array, as described in the Materials and
Methods section. Immunoreactivity was scored as negative, weak, moderate or
strong staining intensity.
Table 2 Disease-free survival for clinicopathological parameters
Variables Na DFS (%) HR 95% CI P-value
HPV-type
Negative 9 89 — — —
16 54 76 2.2 0.3–16.3 0.465
18 23 65 3.7 0.5–29.7 0.216
Other 17 88 1.1 0.1–12.0 0.944
Histopathology
SCC 62 74 0.7 0.3–1.7 0.447
A(S) 41 81
Tumour size
o40mm 59 90 6.1 2.4–15.6 o0.001
X40mm 38 55
Infiltration depth
o15mm 56 88 3.7 1.5–9.0 0.003
X15mm 46 63
Parametrial invasion
Negative 94 81 5.2 2.0–13.1 0.001
Positive 9 33
Vasoinvasion
Negative 48 83 2.1 0.9–4.9 0.086
Positive 52 69
Lymph node metastasis
Negative 79 87 7.2 3.2–16.3 o0.001
Positive 24 42
Resections margins
Negative 77 83 3.0 1.4–6.8 0.007
Positive 26 58
Postoperative radiotherapy
No 47 92 5.1 1.7–15.0 0.003
Yes 56 64
Abbreviations: A(S)¼ adeno(squamous) carcinoma; DFS¼ disease-free survival;
HR¼ hazard ratio; 95% CI¼ 95% confidence interval; HPV¼ human papillomavirus;
SCC¼ squamous cell carcinoma. Univariate Cox-regression analysis for disease-free
survival based on clinicopathological parameters. aTotal number of cases¼ 103; for
some variables, data were not available for all patients. The bold entries place
emphasis on statistically significant P-values.
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DISCUSSION
The present study showed for the first time that CXCR7 was
independently associated with disease recurrence in cervical
cancer. In addition, CXCR7 expression was associated with tumour
size and lymph node status at the time of surgery. These findings
suggest that CXCR7 expression leads to more aggressive tumour
growth and metastasis formation.
CXC chemokine receptor 7 is frequently expressed on embryo-
nic and neoplastic transformed cells, but undetectable or expressed
at very low levels in normal adult tissues (Burns et al, 2006; Miao
et al, 2007). Experiments using mouse models showed that
increased CXCR7 expression resulted in a larger tumour size and
an enhanced metastatic potential (Miao et al, 2007). Previously,
CXCR7 has been shown to be associated with disease-specific and
disease-free survival in non-small cell lung cancer (Iwakiri et al,
2009). In the present study, we showed that in cervical cancer as
well, disease-free survival was lower in CXCR7-positive cases
(63%) than in CXCR7-negative cases (90%, HR¼ 4.3, 95% CI
1.7–11.0, P¼ 0.002), even when adjusting for other prognostic
factors. Disease-specific survival was also strongly associated with
CXCR7 expression. Therefore, CXCR7 might be used as a
prognostic marker to predict disease recurrence, with additive
predictive value to lymph node status and tumour size.
The current data also showed that CXCR7 was often co-
expressed with EGFR or CXCR4 (double positive) or both (triple
positive), with only four single-positive cases, supporting the
hypothesis that CXCR7 requires other molecules for optimal
intracellular signalling. Sierro et al (2007) have shown that CXCR7
forms heterodimers with CXCR4 and Singh and Lokeshwar (2011)
have shown that CXCR7 is capable of forming heterodimers with
EGFR. Activation of HEK293 cells co-expressing CXCR7 and
CXCR4 results in a stronger calcium flux when compared with cells
expressing CXCR4 alone, whereas CXCR7 was unable to induce
calcium flux by itself (Burns et al, 2006; Sierro et al, 2007).
However, CXCR7 is capable of signalling through MAPK/AKT
pathways, indicating that EGFR, which also signals through
MAPK/AKT, might be an alternative co-receptor for CXCR7
(Grymula et al, 2010). Interestingly, in CXCR7- and CXCR4-
positive rhabdomyosarcoma cells, CXCL12-induced chemotaxis
could still be observed after blocking CXCR4, although strongly
reduced when compared with controls (Grymula et al, 2010).
Similarly, in CXCR7-positive, CXCR4-negative 4T1 breast cancer
cells, CXCR7 expression promoted tumour growth and progres-
sion of lung metastases in mice (Miao et al, 2007). As
rhabdomyosarcoma cells and 4T1 breast cancer cells are both
EGFR-positive, CXCR7 might signal through heterodimerisation
with EGFR in case CXCR4 is absent or blocked (Dykxhoorn et al,
2009; Herrmann et al, 2010). However, although our data support
this hypothesis, as a positive correlation was observed between
CXCR7 and EGFR expression, functional studies on cervical cancer
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Figure 2 Disease-free survival in cervical cancer patients with positive or negative CXCR7 expression (A), CXCR7-negative/CXCR7 single-positive cases,
CXCR7–positive, and either EGFR- or CXCR4-positive (double positive) cases and CXCR7-, EGFR- and CXCR4-positive (triple positive) cases in all
patients (B) and in patients with squamous cell carcinoma (C). P-values were obtained using Cox-regression analysis; see Table 3 for HRs and CIs.
Table 3 Disease-free survival for CXCR7, EGFR, CXCR4 and CXCL12
protein expression
Variables N a DFS (%) HR 95% CI P-value
CXCR7
Negative 58 90 4.3 1.7–11.0 0.002
Positive 43 63
EGFR
Low 35 86 2.3 0.9–6.4 0.095
High 59 71
CXCR4
Negative 36 78 1.2 0.5–2.9 0.625
Positive 61 74
CXCL12
Negative 13 69 0.8 0.3–2.3 0.653
Positive 79 75
CXCR7/EGFR/CXCR4
CXCR7 negative/single positive 62 89 — — —
Double positive 16 63 3.6 1.2–10.7 0.022
Triple positive 21 62 4.2 1.5–11.7 0.006
CXCR7/EGFR/CXCR4 in SCC
CXCR7 negative/single positive 30 90 — — —
Double positive 14 71 2.7 0.6–12.1 0.193
Triple positive 16 56 5.8 1.5–22.4 0.011
Abbreviations: CXCR¼CXC chemokine receptor; DFS¼ disease-free survival; EGFR¼
epidermal growth factor receptor; HR¼ hazard ratio; 95% CI¼ 95% confidence interval;
SCC¼ squamous cell carcinoma. aTotal number of cases¼ 103; for some variables, data
were not available for all patients. Univariate Cox-regression analysis for disease-free
survival based on the status of CXCR7, EGFR, CXCR4 and/or CXCL12 protein
expression. CXCR7, CXCR4 and CXCL12 expression are divided into negative (intensity
score of 0) and positive (intensity scores of 1, 2 and 3) groups. EGFR expression was
divided into low (intensity scores of 0 and 1) and high (intensity scores of 2 and 3)
expression groups. In addition, co-expression of CXCR7, EGFR and CXCR4 was analysed
as follows: CXCR7-negative cases (n¼ 58) and CXCR7 single-positive cases (n¼ 4) were
combined and compared with double-positive cases (i.e. CXCR7-positive cases with
either high EGFR expression or positive CXCR4 expression), and triple positive cases (i.e.
CXCR7-positive cases with both high EGFR expression and positive CXCR4 expression).
This analysis was also performed after selection of patients with SCC. The bold entries
place emphasis on statistically significant P-values.
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cell lines are required to determine whether CXCR7 and EGFR are
indeed co-dependent for signal transduction. Furthermore,
although HRs were similar for double- and triple-positive cases
in the whole study group, HRs increased in an additive fashion in
squamous cell carcinomas, which indicates that molecular
mechanisms regulating metastasis formation may differ between
histopathological subtypes.
In conclusion, CXCR7 expression was strongly associated with
tumour size, lymph node metastasis, disease recurrence and
poor disease-specific survival, suggesting that CXCR7 expression
leads to a biologically more aggressive tumour. CXC chemokine
receptor 7 might be a promising new prognostic marker in cervical
cancer and may serve as a potential therapeutic target. CXC
chemokine receptor 7 is often co-expressed with CXCR4 and/or
EGFR, which supports the hypothesis that these receptors assist in
CXCR7 signal transduction.
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